Abstract
There is a clinical demand for tools that could distinguish patients who may benefit or suffer from particular systemic treatments. High throughput technologies such as DNA microarray are anticipated as comprehensive tools for development of accurate predictive markers of treatment outcome. Although technical and statistical problems still exist in pharmacogenomic research, rigorous efforts have been made to realize treatment individualization. Clinicians should be prepared for the future use of these new technologies in the clinic through discussion involving patients and various health-care providers.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
